Dynavax Technologies | Pasivo Circulante



Current Liabilities Cambio Fecha
AbbVie USD 38.75B 4.31B 2024-12
Adma Biologics USD 55.54M 10.65M 2024-12
Amgen USD 23.1B 2.79B 2024-12
AstraZeneca USD 27.87B 1.94B 2024-12
Biogen USD 5.53B 103.8M 2024-12
BioMarin Pharmaceutical USD 606.99M 108.67M 2024-12
Bristol-Myers Squibb USD 23.77B 1.14B 2024-12
Dynavax Technologies USD 78.63M 8.6M 2024-12
Gilead Sciences USD 12B 279M 2024-12
Glaxosmithkline GBP 21.7B 238M 2024-12
Merck USD 28.42B 1.17B 2024-12
Neurocrine Biosciences USD 507.7M 78M 2024-12
Novartis USD 28.69B 560M 2024-12
Pfizer USD 43B 216M 2024-12
Regeneron Pharmaceuticals USD 5.7B 2.04B 2024-12
Roche Holding CHF 27.02B 424M 2024-12
Sarepta Therapeutics USD 731.68M 32.2M 2024-12
TG Therapeutics USD 90.68M 34.43M 2024-12
Vertex Pharmaceuticals USD 3.56B 408.5M 2024-12



Dynavax Technologies Pasivo Circulante - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Mar 2025.